![Michael May](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael May
Directeur Général chez
Centre For Commercialization of Regenerative Medicine
Profil
Michael H.
May founded Rimon Therapeutics Ltd., where he worked as Chief Operating Officer from 2006 to 2010.
Dr. May also currently works at Centre For Commercialization of Regenerative Medicine, as President, Chief Executive Officer & Director, CCRM Enterprises Inc, as Chief Executive Officer, ExCellThera, Inc., as Chairman, ExCellThera Ltd., as Chairman, Omniabio, Inc., as Chairman, 20, as Director, Toronto Innovation Acceleration Partners, as Director, The Centre for the Commercialization of Antibodies & Biologics, as Director, and Foundation For Cell & Gene Medicine, as Director.
Dr. May also formerly worked at Alliance for Regenerative Medicine, as Director, The Ontario Institute For Regenerative Medicine, as Director, and AgeX Therapeutics, Inc., as Independent Director from 2019 to 2023.
Dr. May received his doctorate degree in 1998 from the University of Toronto.
Postes actifs de Michael May
| Sociétés | Poste | Début |
|---|---|---|
Toronto Innovation Acceleration Partners
 Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Operates as a commercialization agent | Directeur/Membre du Conseil | - |
Centre For Commercialization of Regenerative Medicine
 Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Provides regenerative medicine-based technologies and cell and gene therapy | Directeur Général | - |
20/20 Vision Centers, Inc.
 20/20 Vision Centers, Inc. Medical/Nursing ServicesHealth Services Provides lasik surgery services | Directeur/Membre du Conseil | - |
ExCellThera Ltd. | Président | - |
ExCellThera, Inc.
 ExCellThera, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company which engages in cell expansion and bioengineering activities | Président | - |
CCRM Enterprises Inc | Directeur Général | - |
Omniabio, Inc.
 Omniabio, Inc. BiotechnologyHealth Technology Develops stem cell and gene therapies | Président | - |
Foundation For Cell & Gene Medicine
 Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine. | Directeur/Membre du Conseil | - |
The Centre for the Commercialization of Antibodies & Biologics
 The Centre for the Commercialization of Antibodies & Biologics Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael May
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░ ░░░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░ ░░░░░░░ ░░░░░░░░░ ░░░ ░░░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Michael May
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
80
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
20/20 Vision Centers, Inc.
20/20 Vision Centers, Inc. Medical/Nursing ServicesHealth Services Provides lasik surgery services | Health Services |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rimon Therapeutics Ltd.
 Rimon Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures medical polymers which helps to treat chronic wounds | Health Technology |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Operates as a commercialization agent | Health Technology |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Health Services |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Provides regenerative medicine-based technologies and cell and gene therapy | Health Technology |
The Ontario Institute For Regenerative Medicine
 The Ontario Institute For Regenerative Medicine Miscellaneous Commercial ServicesCommercial Services Operates as stem cell and regenerative medicine research company | Commercial Services |
AgeX Therapeutics, Inc.
 AgeX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics | Health Technology |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company which engages in cell expansion and bioengineering activities | Health Technology |
ExCellThera Ltd. | |
The Centre for the Commercialization of Antibodies & Biologics
The Centre for the Commercialization of Antibodies & Biologics Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
CCRM Enterprises Inc | |
Omniabio, Inc.
Omniabio, Inc. BiotechnologyHealth Technology Develops stem cell and gene therapies | Health Technology |
Foundation For Cell & Gene Medicine
Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine. |
